Dermata Therapeutics Inc. (DRMA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
Dermata Therapeutics, Inc. DRMA stock is trading higher on Thursday.
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it received approval from U.S. Food and Drug Administration (FDA) of the proprietary name, Xyngari (pronounced zin-gar-ee) (formerly DMT310), for its Phase 3 clinical drug candidate in acne. The proprietary name, Xyngari, is approved pending the successful submission and acceptance of a new drug application (NDA).
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced receipt of a notice of allowance from the United States Patent and Trademark Office of a new patent for its DMT310 product candidate for the treatment of acne. The allowed patent application, entitled "Compositions and methods for the treatment of skin conditions" (U.S. Application No.
Dermata Therapeutics Inc. (DRMA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dermata Therapeutics Inc. ever had a stock split?
Dermata Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gerald T. Proehl CEO | NASDAQ (CM) Exchange | 249845504 CUSIP |
| US Country | 8 Employees | - Last Dividend | 1 Aug 2025 Last Split | 13 Aug 2021 IPO Date |
Overview
Dermata Therapeutics, Inc. is a pioneering clinical-stage medical dermatology company focused on the discovery, development, and eventual market release of novel pharmaceutical products aimed at treating a variety of medical and aesthetic skin conditions and diseases. Since its establishment in 2014, Dermata Therapeutics has dedicated its efforts to address unmet needs within the dermatology community, harnessing cutting-edge science and research to bring forward innovative solutions. The company is headquartered in San Diego, California, reflecting its strategic position within one of the world’s leading biotechnology hubs. Dermata’s commitment to excellence and innovation in dermatological care positions it as a promising player in the field of medical dermatology.
Products and Services
Dermata Therapeutics, Inc. has made significant strides in the development of its pharmaceutical product candidates, focusing on the treatment of both medical and aesthetic skin conditions. The company’s pipeline includes:
- DMT310: This leading product candidate has successfully completed a Phase IIb clinical trial for the treatment of moderate-to-severe acne, demonstrating Dermata’s commitment to tackling prevalent skin conditions with unmet medical needs. Furthermore, DMT310 has also completed a Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, showcasing its potential versatility in treating various dermatological conditions. Currently, DMT310 is undergoing a Phase 2 clinical trial for addressing moderate-to-severe rosacea, further expanding its potential applicability in the dermatologic landscape.
- DMT410: Another innovative product in Dermata’s pipeline, DMT410, has completed Phase Ib POC trials targeting the treatment of axillary hyperhidrosis (excessive underarm sweating) and certain aesthetic conditions. This development signifies Dermata’s venture into addressing both the medical and aesthetic aspects of dermatologic health, indicating a comprehensive approach to skin care.
Contact Information
